open access
Measurement of bronchoconstrictive eicosanoids in chronic obstructive pulmonary disease
open access
Abstract
Material and methods: 29 COPD patients aged 73 ± 8.34, mean FEV1 = 48.64 ± 15.75% of predictive value and 29 healthy controls aged 57.48 ± 10.86, mean FEV1 = 97.17 ± 13.81% of predictive value participated in this study. Samples of urine and blood were taken from COPD patients during exacerbation and in stable state of the disease; LTE4 was determined in urine using commercial enzyme immunoassay (EIA) and 9α11β prostaglandin F2 (9α11βPGF2) — stable metabolite of PGD2 was evaluated in blood and urine using GC/MS.
Results: LTE4 concentration in urine (677.15 vs. 436.4 pg/mg of creatinine; p = 0.035) and 9α11βPGF2 in blood serum (5.35 vs. 3.07 pg/ml; p = 0.007) were significantly higher in exacerbated COPD patients than in control group. There was no difference in LTE4 level in urine and 9α11βPGF2 in blood serum between exacerbated and stable COPD. The urinary 9α11βPGF2 concentration did not differ between all studied groups. We found a positive correlation between smoking history and the urine LTE4 level (r = 0.395; p = 0.002) as well as blood 9α11βPGF2 concentration (r = 0.603; p = 0.001) in COPD patients.
Conclusions: 9α11βPGF2 and LTE4 level in urine did not differ between the stable COPD group and the control group. We also did not find any difference between LTE4 level in urine and 9α11βPGF2 in blood and urine between exacerbated and stable COPD. Finally, LTE4 concentration in urine and 9α11βPGF2 in blood occurred to be significantly higher in exacerbated COPD patients than in control group.
Abstract
Material and methods: 29 COPD patients aged 73 ± 8.34, mean FEV1 = 48.64 ± 15.75% of predictive value and 29 healthy controls aged 57.48 ± 10.86, mean FEV1 = 97.17 ± 13.81% of predictive value participated in this study. Samples of urine and blood were taken from COPD patients during exacerbation and in stable state of the disease; LTE4 was determined in urine using commercial enzyme immunoassay (EIA) and 9α11β prostaglandin F2 (9α11βPGF2) — stable metabolite of PGD2 was evaluated in blood and urine using GC/MS.
Results: LTE4 concentration in urine (677.15 vs. 436.4 pg/mg of creatinine; p = 0.035) and 9α11βPGF2 in blood serum (5.35 vs. 3.07 pg/ml; p = 0.007) were significantly higher in exacerbated COPD patients than in control group. There was no difference in LTE4 level in urine and 9α11βPGF2 in blood serum between exacerbated and stable COPD. The urinary 9α11βPGF2 concentration did not differ between all studied groups. We found a positive correlation between smoking history and the urine LTE4 level (r = 0.395; p = 0.002) as well as blood 9α11βPGF2 concentration (r = 0.603; p = 0.001) in COPD patients.
Conclusions: 9α11βPGF2 and LTE4 level in urine did not differ between the stable COPD group and the control group. We also did not find any difference between LTE4 level in urine and 9α11βPGF2 in blood and urine between exacerbated and stable COPD. Finally, LTE4 concentration in urine and 9α11βPGF2 in blood occurred to be significantly higher in exacerbated COPD patients than in control group.
Keywords
COPD; LTE4; PGD2; bronchoconstrictive eicosanoids


Title
Measurement of bronchoconstrictive eicosanoids in chronic obstructive pulmonary disease
Journal
Advances in Respiratory Medicine
Issue
Article type
Research paper
Pages
120-126
Published online
2012-02-27
Bibliographic record
Pneumonol Alergol Pol 2012;80(2):120-126.
Keywords
COPD
LTE4
PGD2
bronchoconstrictive eicosanoids
Authors
Iwona Gross-Sondej
Jerzy Soja
Krzysztof Sładek
Grażyna Pulka
Wojciech Skucha
Ewa Niżankowska-Mogilnicka